Filing Details
- Accession Number:
- 0001415889-24-029400
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-12-13 21:35:05
- Reporting Period:
- 2024-12-13
- Accepted Time:
- 2024-12-13 21:35:05
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1604821 | Natera Inc. | NTRA | Services-Medical Laboratories (8071) | 010894487 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1646382 | Matthew Rabinowitz | C/O Natera, Inc. 13011 Mccallen Pass Building A Suite 100 Austin TX 78753 | Executive Chairman | No | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2024-12-13 | 28,681 | $164.61 | 2,520,499 | No | 4 | S | Direct | |
Common Stock | Disposition | 2024-12-13 | 75,323 | $165.45 | 2,445,176 | No | 4 | S | Direct | |
Common Stock | Disposition | 2024-12-13 | 45,769 | $166.45 | 2,399,407 | No | 4 | S | Direct | |
Common Stock | Disposition | 2024-12-13 | 4,927 | $167.39 | 2,394,480 | No | 4 | S | Direct | |
Common Stock | Disposition | 2024-12-13 | 5,300 | $168.35 | 2,389,180 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock | 84,000 | Indirect | By spouse |
Footnotes
- The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 13, 2024.
- The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $164.00 to $164.99 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $165.00 to $165.99 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $166.00 to $166.98 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $167.00 to $167.92 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $168.15 to $168.89 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.